{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-084735","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.492813+00:00","generated_at":"2026-06-08T09:22:02.136035+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Relmada reports Q3 net loss $22.0M; cash $106.3M; REL-1017 Phase 3 enrollment on track","bullets":["Q3 net loss $22.0M ($0.73/share) vs $39.4M ($1.31) YoY.","R&D expense $10.5M, down from $30.5M due to Reliance I/III completion.","Cash and equivalents $106.3M at Sep 30, 2023 vs $148.3M at Dec 31, 2022.","Phase 3 REL-1017 trials for MDD: Reliance II enrollment on track for H1 2024; Relight for H2 2024.","Psilocybin program: Phase 1 in steatotic liver disease to start early 2024, Phase 2a planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-084735","json":"https://secwatch.observer/filing/0001213900-23-084735.json","markdown":"https://secwatch.observer/filing/0001213900-23-084735.md","text":"https://secwatch.observer/filing/0001213900-23-084735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/0001213900-23-084735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/ea187924-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:22:02.136035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f85b9484a37fdff253c76d03362d85758726248","claim":"RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2023 results: net income Net loss of $22.0 million, EPS $0.73 per basic and diluted share.","evidence_excerpt":"Net loss for the three months ended September 30, 2023, was $22.0 million, or $0.73 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/0001213900-23-084735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Net income","value":"Net loss of $22.0 million"},{"label":"EPS","value":"$0.73 per basic and diluted share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"43856b71e99be61ca5ef4c5a598ef64713109c9b","claim":"RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2023 results: net income Net loss of $73.6 million, EPS $2.45 per share.","evidence_excerpt":"Net loss for the nine months ended September 30, 2023 and 2022 was $73.6 million and $119.1 million, respectively. The Company had a net loss of $2.45 and $4.04 per share for the nine months ended September 30, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/0001213900-23-084735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2023"},{"label":"Net income","value":"Net loss of $73.6 million"},{"label":"EPS","value":"$2.45 per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}